

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
TRADEMARK EXAMINING DIVISION

----- X
In re Application of: Glaxo Group Limited :
: Trademark Law Office:
Serial No.: 88-406770 : 103
:
Filed: April 29, 2019 : Examining Attorney:
: W. Wendy Jun
Mark: Shape Only :
----- X

Commissioner for Trademarks
P.O. Box 1451
Alexandria, Virginia 22313-1451

Amendment and Response to Office Action

In response to the Office Action dated September 19, 2019, Applicant respectfully amends its Application to seek registration of the Mark under Section 2(f) of the Lanham Act, 15 U.S.C. §1052(f), based on acquired distinctiveness. In support of this response, GSK submits that the Mark has become distinctive of the goods through the Applicant's exclusive and continuous use of the Mark in commerce that the U.S. Congress may lawfully regulate for at least the five years immediately before the date of this statement and refers to the attached Declaration of Andrew Thomas, which provides further support of the Mark's acquired distinctiveness.

Based on the foregoing, GSK respectfully requests that its Mark be permitted to proceed to publication.